New Evidence of Demodex Mite Infestations in Rosacea

New evidence of Demodex infestations in rosacea

A review study published in the September 2017 issue of the Journal of the American Academy of Dermatology supports the role of Demodex mites in rosacea. Ying Shuo-Chang, MD, and Yu-Chen Huang, MD, of Taipei Medical University Hospital, Taiwan, performed a literature search in PubMed, MEDLINE, and EmBase databases from inception through October 31, 2016. They searched the terms “Demodex” and “Demodex Mites” combined with “Rosacea.” All studies included in their review and meta-analysis were human clinical trials published in English.

Bonti Releases Phase 2A Clinical Study Data for its Botulinum Toxin Product

New E serotype E botulinum toxin completes first clinical trial

Bonti, a clinical-stage biotechnology company, has announced topline results of the first clinical study of its lead product candidate, EB-001, in glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours) and short duration of effect (about 4 weeks).

Valeant Dermatology Is Now Ortho Dermatologics

Humphries Announces Rebranding to Ortho Dermatologics

Valeant is rebranding its dermatology products under the name Ortho Dermatologics, which was acquired by Valeant in 2011. The rebranding coincides with the company’s launch of SILIQ, a biologic drug approved for the treatment of psoriasis. “The branding under Ortho Dermatologics allows us to showcase what we have as a company,” says William (Bill) Humphries, executive vice president of dermatology at Valeant. “We have more than 100 years of dermatology experience on the team now and we have a portfolio of dermatology products that, I think, is unrivaled in the industry.”

Ohio becomes seventh state to pass ASDSA SUNucate legislation

Ohio is seventh state to improve access to sunscreens

In July, Ohio became the seventh state to pass SUNucate legislation, a nationwide effort led by the American Society for Dermatologic Surgery Association (ASDSA). The law eliminates barriers prohibiting students from possessing and using over-the-counter sunscreen by exempting these products from ”medication bans” in schools that require a physician’s note or prescription.

In addition to Ohio, Alabama, Arizona, Florida, Louisiana, Utah and Washington state have also approved similar measures this year.

Thermi Co-Founder Joins Ideal Implant Board of Directors

Ideal Implant adds new talent.

Ideal Implant, founded in 2006 to develop, manufacture and market the saline IDEAL IMPLANT Structured Breast Implant has appointed Paul Herchman, co-founder and former CEO of ThermiGen, to its board of directors. He will act as a consultant in corporate development. Current board member Kevin Morano will assume the role of chief financial officer, continuing to lead the company's financial strategy, and Gabe Walters has been promoted from national sales director to vice president of U.S. sales.